9月12日至13日，由北京市海淀区人民政府指导，中关村科学城管委会与CSGCT中国细胞与基因治疗联 盟共同主办，HIEA医疗创新生态联盟、动脉网承办的中国细胞与基因治疗大会（CSGCT）在北京举 行。大会以"立足监管、汇聚智慧、链接全球、共创未来"为核心理念，"全球市场 中国力量"为主题， 设立1场主论坛、15场分论坛及2场项目路演，吸引包括10余位国际CGT领军人物的科学家、临床医生、 企业家、投资者等近2000位嘉宾参会，共商细胞与基因治疗发展大计。 会议期间，CSGCT中国细胞与基因治疗联盟宣告成立。该联盟搭建集科学研究、沟通协作于一体的国 际化平台，助力细胞与基因治疗领域实现更广泛的国际合作与资源共享。会议还发布《中国细胞与基因 治疗产业发展及监管政策解读蓝皮书》，为CGT产业与监管的深度对话搭建权威桥梁。搭建全球未来医 药健康产业孵化平台，依托中关村前孵化创新中心，全面升级建设数据底座、技术平台与保障机制，推 动CGT、多组学和精准医疗、脑机接口、AI医疗四个核心技术领域的发展，为北京打造世界领先的未 来产业策源高地注入强劲动力，助推细胞与基因治疗技术在海淀这片创新热土上实现跨越式发展。 会上，As ...

"作为制度创新先行先试区，海淀区在强化原始创新策源功能、打造国际一流营商环境的同时，全力推 动CGT产业全链条发展"，中关村科学城管委会产业促进三处副处长袁学勤介绍道，政策层面，发布行 动计划与若干措施，为产业发展锚定方向。空间上，释放专业CGT产业聚集区，为企业提供优质发展载 体。服务方面，培育全球未来医药健康产业孵化平台，设立北京药品医疗器械创新服务站（海淀站）， 提供一站式服务。此外，积极开放医疗应用场景，促进医企深度合作。更值得一提的是，建设全国首个 医药健康可信数据空间，整合多元数据，为产业创新注入强劲动力，助力CGT产业迈向新高度。 会议首日，中国细胞与基因治疗联盟宣告成立，由美国ASGCT的创始人之一Mark Kay教授共同创立， 未来将保持密切合作，搭建集科学研究、沟通协作于一体的国际化平台，助力细胞与基因治疗领域实现 更广泛的国际合作与资源共享。 会上发布《中国细胞与基因治疗产业发展及监管政策解读蓝皮书》，为CGT产业与监管的深度对话搭建 权威桥梁。 9月12日至13日，中国细胞与基因治疗大会（CSGCT）在北京海淀区举行。大会在北京市海淀区人民政 府的指导下，由中关村科学城管委会与CSGC ...

Group 1 - The core viewpoint of the article emphasizes that the success of China's cell and gene therapy (CGT) industry will depend on the collaborative development of technological innovation, regulatory science, payment systems, and industry chain maturity [1] - The "Blue Book on the Development and Regulatory Policy Interpretation of China's Cell and Gene Therapy Industry" was released during the conference, highlighting the potential for China to play a more critical role in the global CGT field, ultimately benefiting patients worldwide [1] - Beijing has ranked first in the number of medical device products approved for market in the past three years, and third in the approval of innovative Class 1 drugs, with the medical and health industry in Beijing projected to reach a scale of 1.06 trillion yuan in 2024, representing an 8.7% year-on-year growth [1] Group 2 - Haidian District leverages its strong educational and clinical resources, including 37 higher education institutions and 57 hospitals, to create a "talent highland" for innovation and research in the field of cell and gene therapy [2] - The district is home to several innovative companies focused on CGT drug development, providing continuous innovation momentum for cutting-edge fields [2] - A global future pharmaceutical health industry incubation platform was launched, aimed at promoting the development of four core technology areas: CGT, multi-omics and precision medicine, brain-computer interfaces, and AI healthcare [2] - The establishment of the China Cell and Gene Therapy Alliance (CSGCT Board) aims to create an international platform for scientific research and collaboration, facilitating broader international cooperation and resource sharing in the CGT field [2]

Group 1 - The China Cell and Gene Therapy Conference (CSGCT) was held, co-hosted by the Zhongguancun Science City Management Committee and the CSGCT Alliance, marking the establishment of the CSGCT Board [1][2] - Beijing has ranked first in the number of approved medical device products in the past three years and third in the approval of innovative Class 1 drugs, with the pharmaceutical and health industry expected to reach a scale of 1.06 trillion yuan in 2024, representing an 8.7% year-on-year growth [1] - Haidian District has leveraged its educational and clinical resources, including 37 higher education institutions and 57 hospitals, to create a "talent highland" for innovation in cell and gene therapy (CGT) [1] Group 2 - The "Blue Book on the Development and Regulatory Policy of China's Cell and Gene Therapy Industry" was released, providing authoritative reference for industry and regulatory dialogue, aimed at advancing four core technology areas: CGT, multi-omics and precision medicine, brain-computer interfaces, and AI healthcare [2] - The newly established CSGCT Alliance will focus on comprehensive planning across various aspects such as policy support, academic research, clinical trials, industry implementation, international cooperation, talent cultivation, and public education to address common challenges in China's CGT industry [2]

Group 1 - The China Cell and Gene Therapy Alliance was established during the CSGCT conference, which aims to promote innovation in the cell and gene therapy (CGT) sector [1][2] - Beijing's medical device product approvals have ranked first in the country over the past three years, with the medical health industry expected to reach a scale of 1.06 trillion yuan in 2024, marking an 8.7% year-on-year growth [1] - Haidian District has developed a "talent highland" in CGT, leveraging resources from 37 universities and 57 hospitals, fostering innovation through companies like Bitou Biotechnology and Yimiao Shenzhou [1] Group 2 - The newly launched global future medical health industry incubation platform will focus on four core technology areas: CGT, multi-omics and precision medicine, brain-computer interfaces, and AI in healthcare [2] - The CSGCT conference is one of the most influential international meetings in the CGT field, featuring a main forum and 15 sub-forums covering topics such as gene therapy, immune cell therapy, and tumor vaccines [2] - The platform aims to create a comprehensive service system for the medical health industry, facilitating the entire process from technology screening to market transactions, and attracting global innovation resources [2]